ALX ONCOLOGY HOLDINGS INC (ALXO) Form 8-K — Jun 30, 2026
Corey Goodman, Ph.D., co-founder and Chairman of ALX Oncology, has resigned from the Board effective June 29, 2026, for personal reasons with no disagreement cited with the company on operations, policies, or practices. The Board appointed Scott Garland, an independent director since November 2022 with over 30 years of biopharmaceutical industry experience, as the new Chairman. The company also named Michael Listgarten as General Counsel, who previously held legal leadership roles at RAPT Therapeutics, Adamas Pharmaceuticals, Principia Biopharma, and Genentech.
Price after filing
Close on the filing date to close N calendar days later (from $2.07). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.